Evaluating Blood MicroRNAs to Diagnose and Monitor First Episode Schizophrenia and Predict Response to Aripiprazole or Risperidone Treatment

What this Trial Is About

Researchers are exploring whether tiny molecules called microRNAs miRNAs found in special brain-derived packages, known as neural-derived extracellular vesicles NDEs, can serve as helpful indicators for schizophrenia. This study focuses on 80 individuals recently diagnosed with first-episode schizophrenia and beginning treatment with aripiprazole or risperidone, alongside 80 healthy volunteers. The goal is to find quicker, more accurate ways to diagnose schizophrenia and predict treatment response using these blood-based biomarkers. Participants with first-episode schizophrenia will receive natural treatment prescribed by their psychiatrists with either aripiprazole or risperidone. Blood samples will be collected from these participants at the start of treatment and again after 12 weeks to analyze NDE miRNAs. Healthy volunteers will provide a single baseline blood sample for comparison. The study involves advanced miRNA sequencing techniques and genetic analysis to identify differences and treatment-related changes. During the study, participants will undergo clinical assessments and neurocognitive testing at baseline and after 12 weeks. Blood samples will be analyzed for brain-specific miRNAs to evaluate their diagnostic and predictive value. Researchers will measure how well these miRNAs distinguish schizophrenia cases from healthy individuals and predict treatment response. The study will monitor participant safety and consent throughout, with a total participation duration of 12 weeks for patients and a single visit for healthy volunteers.

MicroRNAs as Biomarkers in First Episode Schizophrenia